Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.
Natalia Nekhotiaeva, Irene L Vargas, Birger Sjöberg, Leif Dahllund, Vendela Parrow, Helena Nordström, Ruth Moulson, Sabin Llona-Minguez, Ulf Martens, Tobias Koolmeister, Fredrik Klingegård, Duy Duc Vo, Björn Glinghammar, Jianping Liu, Anders Eriksson, Maria Häggblad, Si Min Zhang, Stella Karsten, Ingrid Almlöf, Amanda Bögedahl Jensen, Christina Kalderén, Malin Jarvius, Thomas Helleday, Sara Häggblad, Evert J Homan, Ulrika Warpman Berglund, Pål Stenmark, Johannes Meiser, Martin Scobie, Per I Arvidsson, Hans E Krokan, Stefan Knapp, Johan Wannberg, Robert Gustafsson, Ann-Sofie Jemth, Therese Pham, Camilla Göktürk, Richard Svensson, Antonio Sarno, Karl S A Vallin, Alanna C Green, Sanjay Borhade, Elisée Wiita, Olga Loseva, Petra Marttila, Martin Henriksson, Nina M S Gustafsson, Nadilly Bonagas, Kumar Sanjiv, Maurice Michel, Neeraj Garg, Andreas Krämer, Katarina Färnegårdh, Petar Iliev, Matthieu Desroses, Ben Kunz, Linda Pudelko, Eldar Abdurakhmanov, Victoria Cookson, Cynthia B J Paulin, Christoffer Bengtsson, Emma R Scaletti, Yasmin Andersson, Martin Haraldsson, Judith E Unterlass, Azita Rasti, Lars Sandberg, Nicole Kiweler
Nature cancer 2022;3(2):156-172